Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 5,350,000 shares of its common stock at an offering price of $33.00 per share in a private placement to certain qualified institutional buyers and institutional accredited investors. Gross proceeds of the private placement are expected to be approximately $176.6 million, before deducting placement agent fees and other expenses. The private placement is expected to close on September 20, 2022, subject to the satisfaction of customary closing conditions.
The private placement was led by Redmile Group, with participation by Boxer Capital, Braidwell LP, EcoR1 Capital, Vivo Capital, Great Point Partners, LLC, Adage Capital Management, Logos Capital, Maven Investment Partners US, Driehaus Capital Management, Acuta Capital Partners, CaaS Capital Management, Woodline Partners LP, Walleye Capital and other investors, including two large mutual funds.

Ventyx currently intends to use the net proceeds from the proposed private placement, together with existing cash and cash equivalents, to fund the clinical development of VTX958, VTX002, VTX2735 and VTX3232, the preclinical development of other programs, research activities and working capital and other general corporate purposes. With the proceeds from the private placement, Ventyx expects to extend its cash runway into 2025. This cash estimate is a preliminary estimate and is based on information available to management as of the date of this private placement, and these estimates could change.

Porsche AG is set to begin trading on Sept. 29.

Volkswagen's IPO Price Range for Porsche AG in Line With Expectations -- Market Talk
2:47 am ET September 19, 2022 (Dow Jones) Print
0647 GMT - Volkswagen and its shareholder Porsche SE will likely trade slightly higher on Monday after releasing more details about the planned listing of sports-car maker Porsche AG, a trader says. While both companies' shares aren't expected to rise significantly, because the new details are largely in line with expectations, the forecasted proceeds from the unit's IPO will be available for investments in technologies and are clearly positive, the trader says. Volkswagen is targeting a Porsche AG valuation of up to EUR75 billion, and intends to list the subsidiary's shares at between EUR76.50 and EUR82.50, in the middle range of analysts' expectations. Porsche AG is set to begin trading on Sept. 29. (barcelonaeditors@dowjones.com)


(END) Dow Jones Newswires

September 19, 2022 02:47 ET (06:47 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

SONN revenues are $53,000. per employee. > According to MarketWatch.

Tank city > folks getting pounded on spac after spac. I didn't buy any shares; but took several minutes in premarket to set up this ihub board.

FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday.

FOXO Technologies Shares Lower on Debut After SPAC Business Combination
11:48 am ET September 16, 2022 (Dow Jones) Print

By Stephen Nakrosis


Shares of FOXO Technologies Inc., which debuted on the NYSE American exchange Friday, were trading lower just before midday.

On Thursday, FOXO and special-purpose acquisition company Delwinds Insurance Acquisition Corp. announced the completion of their business combination. Shares of the combined company, FOXO Technologies, began trading under the symbol FOXO on Friday.

At 11:39 a.m. ET, the company's stock had declined 44% to trade at $4.69. The shares opened the day's trading at $7.29.

FOXO said it is focused on "commercializing longevity science" through products and services that serve the life insurance industry.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

September 16, 2022 11:48 ET (15:48 GMT)

FOXO Technologies to List on NYSE American Following Successful Business Combination with Delwinds Insurance Acquisition Corp
5:47 am ET September 16, 2022 (Benzinga) Print
FOXO Technologies Inc. ("FOXO" or the "Company"), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced the completion of its business combination (the "Business Combination") with Delwinds Insurance Acquisition Corp. (NYSE: DWIN) ("Delwinds"), a publicly traded special purpose acquisition company.

The products and services FOXO is developing combine longevity science with life insurance to: (i) support consumer health and wellness engagement, and (ii) simplify the consumer underwriting journey.

The combined company will operate under the name "FOXO Technologies Inc.," and will be led by Chief Executive Officer Jon Sabes. Commencing at the open of trading on September 16, 2022, FOXO's Class A common stock are expected to trade on the NYSE American exchange under the symbol "FOXO". FOXO's warrants will continue to trade on the NYSE exchange under the symbol "FOXO WS", and it is anticipated that trading of the warrants will move to the NYSE American exchange shortly. Upon the consummation of the Business Combination, each outstanding unit of Delwinds was automatically separated into one share of Delwinds Class A common stock and one half of one Delwinds warrant and each share of Delwinds class A common stock and each whole warrant of Delwinds was exchanged for one FOXO common share and one FOXO warrant, exercisable into shares of FOXO Class A common stock, respectively. The warrant exercise price for each FOXO warrant is $11.50.

The transaction was approved by Delwinds' stockholders at its special meeting held on September 14, 2022. Over 91% of the votes cast on the business combination proposal at the special meeting were cast in favor of approving the business combination.

Advisors

Cantor Fitzgerald acted as Capital Markets Advisors to Delwinds. Ellenoff, Grossman & Schole LLP acted as legal advisor to Delwinds. Mitchell Silberberg & Knupp LLP and Stinson LLP acted as legal advisors to FOXO

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

FOXO Technologies Inc., formerly Delwinds Insurance Acquisition Corp., is a technology platform company. The Company is focused on commercializing longevity science through products and services that serve the life insurance industry. The Company's epigenetic technology applies artificial intelligence (AI) to deoxyribonucleic acid (DNA) methylation to identify molecular biomarkers of human health and aging through its services platform, called FOXO Labs, to offer life insurance carriers consumer engagement and saliva-based underwriting technology services. Its consumer engagement platform incorporates health and wellness information related to longevity science into life insurance products. Its underwriting technology integrates saliva-based epigenetic biomarkers into accelerated underwriting protocols. The Company is also developing an insurance products platform, called FOXO Life.

Rachel Balkovec won her debut managing the Low-A Tampa Tarpons in the New York Yankees' system, becoming the first woman to skipper a team affiliated with a major league club. She is a manager and not a player.

Marths's Vineyard is a designated "sanctuary city" . But now the wealthy Democrats that have residences there are now doing a "180° " . They scream " not in my backyard! Imediate removal of the illegal border crossers has taken place.

AAOI @ 3.90 up 55%

Why Applied Optoelectronics Shares Are Popping Off Friday
1:11 pm ET September 16, 2022 (Benzinga) Print
Applied Optoelectronics Inc (NASDAQ: AAOI) shares are trading higher by 42.8% to $3.57 during Friday's trading session after the company announced the sale of its Chinese manufacturing facilities to Yuhan Optoelectronic Technology for $150 million.

What Happened?

The company anticipates that the transaction will be completed in 2023 and is subject to customary closing conditions and regulatory approvals.

"The significant proceeds from this transaction will enable us to make strategic investments in higher margin and higher growth opportunities," said Dr. Thompson Lin, Applied Optoelectronics Inc Founder, President and Chief Executive Officer.

"After careful consideration, we concluded that it is in the best interest of the company and our shareholders for AOI to exit the transceiver market and focus our resources on our CATV business and manufacturing lasers and laser components for the datacenter, CATV, telecom, and FTTH markets. Further, we believe that this transaction opens up new opportunities for customer expansion with our existing datacenter laser business, which has a large addressable market."

See Also: So Is Dogecoin Heading Back to 5 Cents Or Making A Run To 10 Cents? Survey Says...

$150,000,000. > Investors are forward looking!

AAOI > ramping up > Applied Optoelectronics Is Maintained at Outperform by Northland Capital Markets
September 16, 2022 (Dow Jones) Print

Ratings actions from Benzinga: https://www.benzinga.com/stock/AAOI/ratings


(END) Dow Jones Newswires

September 16, 2022

Applied Optoelectronics Is Maintained at Outperform by Northland Capital Markets
9:53 am ET September 16, 2022 (Dow Jones) Print

Ratings actions from Benzinga: https://www.benzinga.com/stock/AAOI/ratings


(END) Dow Jones Newswires

September 16, 2022 09:53 ET (13:53 GMT)

Biden should open the Canadian border. Very tough security on our northern border.

BEAT > 3.5M trading float. Running strong into closing bell.

Investors are forward looking! Tutes, endowment funds, pension funds, and mutual funds accumulating!

BEAT IS A GREAT $$$$$ OPPORTUNITY.

Sold my shares above $7.00 prices. Good run for a few day trades!

MEGL is a great $$$$$ opportunity.

MEGL > 6.83

MEGL > 6.63

MEGL up 5% @ 6.55 > primed for another upside run.

Let's go MEGL !

Heavy volume day! > We could see momo/fomo gear up this week!

MEGL

Definitely a royal flush! ..... lol.

$ATXI a play with a small 670k float, reverse merger with a licensing deal with AstraZeneca, a “possible” FDA approval and an IPO all in one.

Nice alert! > up 111%


$ATXI reverse split up 20% now float will become 670,000

Stocks Moving Premarket:
Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split.
Akerna Corp. (NASDAQ: KERN) shares rose 37.6% to $0.1789 in pre-market trading after gaining 8% on Tuesday.
Zovio Inc (NASDAQ: ZVO) rose 19.5% to $0.2930 in pre-market trading. Zovio, last month, said Q2 EPS and sales were down year over year.
Ampio Pharmaceuticals, Inc. (NYSE: AMPE) rose 18.4% to $0.1160 in pre-market trading after gaining around 5% on Tuesday.
Delwinds Insurance Acquisition Corp. (NYSE: DWIN) rose 18.4% to $10.20 in pre-market trading after dropping 11% on Tuesday.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 11.1% to $0.4588 in pre-market trading after jumping 22% on Tuesday.
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) rose 11% to $2.42 in pre-market trading. Eos Energy Enterprises, last month, posted a Q2 loss of $1.01 per share.
ContraFect Corporation (NASDAQ: CFRX) rose 10.5% to $0.2550 in pre-market trading. ContraFect, last month, posted a Q2 loss of $0.46 per share.
180 Life Sciences Corp. (NASDAQ: ATNF) rose 10.4% to $0.9012 in pre-market trading after declining around 8% on Tuesday.
Trinity Place Holdings Inc. (NYSE: TPHS) rose 9.2% to $1.30 in pre-market trading after surging 11% on Tuesday.
E-Home Household Service Holdings Limited (NASDAQ: EJH) rose 8.8% to $0.2095 in pre-market trading.
Nikola Corporation (NASDAQ: NKLA) rose 5.4% to $5.30 in pre-market trading following upgrade at BTIG from Neutral to Buy, according to Reuters.

Yankees should have conehead shape hand mitts. At least adding an extra 15 inches . The hand mitts should also. be an extra 15 inches . Those extra inches help on close calls when sliding into second bsse.

ARQQW up 70% @ 1.15

Arqit Quantum Chief Executive David Williams will present during an H.C. Wainwright conference > NOW <

Arqit Quantum Inc is a United Kingdom-based cybersecurity technology company. The Company supplies quantum encryption platform-as-a-service, which makes the communications links of networked device secure against the attacks. The Company’s product, QuantumCloud, enables devices to download a lightweight software agent, which creates keys in partnership with another device. QuantumCloud able to create limitless volumes of keys in limitless group sizes and regulates the secure entrance and exit of a device in a group. Its platform also solves the problems of legacy encryption techniques.

VTYX IS A GREAT $$$$$ OPPORTUNITY.

Ventyx Shares Surge 59% After Bristol Myers Drug Approved Without Black-Box Warning
1:33 pm ET September 12, 2022 (Dow Jones) Print
By Josh Beckerman


Ventyx Biosciences Inc. shares rose 59% to $36.80 after analysts mentioned favorable signs related to the approval of Bristol Myers Squibb Co.'s psoriasis drug Sotyktu.

Stifel, Evercore ISI and Oppenheimer analysts noted that the U.S. Food and Drug Administration approval of the TYK2 inhibitor didn't include a black-box warning.

Jeff Jones and Leland Gershell at Oppenheimer wrote that "we see this as a significant win for deucravacinitib, VTYX and other TYK2 developers, substantially differentiating the TYK2 inhibitors from the JAK 1-3 inhibitors."


Write to Josh Beckerman at josh.beckerman@wsj.com

Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line Maintenance
9:11 am ET September 12, 2022 (Benzinga) Print
Clovis Oncology Inc (NASDAQ: CLVS) announced results from a subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca versus placebo in advanced ovarian cancer.
The data showed that Rubraca as a first-line maintenance treatment improved progression-free survival (PFS) versus placebo across disease risk subgroups, including surgical outcome, response to first-line chemotherapy, and additional analyses in other subgroups.
Patients who received Rubraca as maintenance therapy showed benefit regardless of surgical outcome, whether there was complete resection (R0) during cytoreductive surgery or not.
Among HRD-positive patients:
Patients who demonstrated a partial response to first-line chemotherapy; Rubraca (n=33), median PFS of 14.8 months; placebo (n=9), median PFS of 9.1 months.
Patients who demonstrated a complete response to first-line chemotherapy; Rubraca (n=38), median PFS of 25.8 months; placebo (n=4), median PFS not yet reached.
Among the ITT population:
Patients who demonstrated a partial response to first-line chemotherapy; Rubraca (n=76), median PFS of 12.2 months; placebo (n=22), median PFS of 6.4 months.
Patients who demonstrated a complete response to first-line chemotherapy; Rubraca (n=73), median PFS of 15.6 months; placebo (n=11), median PFS of 6.4 months.
Safety was similar between the subgroups analyzed.
Price Action: CLVS shares are up 13% at $1.30 during the premarket session on the last check Monday.

1.52

CLVS running too! > Clovis Oncology shares are trading higher after the company presented data from its Phase 3 ATHENA trial which showed Rubraca as a first-line maintenance treatment improved progression-free survival in advanced ovarian cancer.

PXMD

Clovis Oncology shares are trading higher after the company presented data from its Phase 3 ATHENA trial which showed Rubraca as a first-line maintenance treatment improved progression-free survival in advanced ovarian cancer.